We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Rapid Screening Test Developed for Ebola Virus

By LabMedica International staff writers
Posted on 12 Oct 2017
During the Ebola outbreak in Africa in 2014, patients tested for the disease had to provide a blood sample for testing in a specialist laboratories by highly trained staff. More...
There are only a few of these facilities in the world.

Each diagnosis of the Ebola virus (EBOV) genome taking between 5-8 hours to confirm, and as yet there is no solution for reliably deploying at the point of need the gold standard diagnostic method, real time quantitative reverse transcription polymerase chain reaction (RT-qPCR), in a laboratory infrastructure-free manner.

An international team of scientists collaborating with those at Northumbria University (Newcastle Upon Tyne, UK) have demonstrated the direct performance of RT-qPCR on fresh blood using far-red fluorophores to resolve fluorogenic signal inhibition and controlled, rapid freeze/thawing to achieve viral genome extraction in a single reaction chamber assay. The team focused on the Trombley primer and probe sets for the EBOV GP and NP genes, considering the human RP assay as a control, and an MS2 Escherichia coli phage-specific assay set for fluorescent probe- or intercalator-based blood tolerance studies. Plate-based RT-qPCR assays were carried out on an ABI 7500.

The new point of care diagnostic platform is called EbolaCheck, which can be deployed to the scene of an outbreak. The test can now be carried out on an amount of blood that is 700 times smaller than previously needed, literally a drop obtained by 'pin pricking' a finger, and it now takes less than 70 minutes to complete. As a result, the test is much safer to administer, requires minimal training and reduces the cost of diagnosis significantly. Crucially, its performance is comparable to laboratory testing, meaning any patient with symptoms of Ebola can be safely and reliably diagnosed. The test uses proprietary technology developed by BioGene Ltd.

Sterghios A. Moschos, FRCS, FIBMS, an associate professor and lead investigator said, “The development of this pioneering technology could essentially save lives and reduce the spread of the disease, which is crucial in a humanitarian crisis. Due to there being no further cases since it was developed, to date, it has not been possible to take the test out of the lab, into the field, where the patient needs it. However, it can be deployed anywhere, the frontline in Africa where this disease is found, as well as international airports and ports, to help stop the disease from spreading and to prevent disruption of international trade and travel. It could also be used in the diagnosis of other infectious diseases.” The study was published on September 25, 2017, in the journal Chemical Science.

Related Links:
Northumbria University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.